Octocog alfa, Plasma/Albumin-Free Method | springermedizin.de

Springer Medizin

nach oben

Drugs

Erschienen in:

01.12.2005 | Adis Drug Profile

Octocog alfa, Plasma/Albumin-Free Method

A Viewpoint by Jørgen Ingerslev

verfasst von: Jørgen Ingerslev

Erschienen in: Drugs | Ausgabe 18/2005

Einloggen, um Zugang zu erhalten

Excerpt

Substitution therapy with a concentrate of coagulation factor VIII is the mainstay in the management of bleeding episodes in patients with classic congenital haemophilia A. In the manufacture of factor VIII, plasma from healthy donors was the major source of material until products derived from recombinant DNA technologies became available in the mid-1990s. Owing to the high incidence of transmission of health- and life-threatening human pathogens, such as HIV and hepatitis C virus, from plasma-derived products, the new recombinant factor VIII concentrates were seen as a major safety advantage for recipients. …

Titel: Octocog alfa, Plasma/Albumin-Free Method
A Viewpoint by Jørgen Ingerslev
verfasst von: Jørgen Ingerslev
Publikationsdatum: 01.12.2005
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 18/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565180-00007

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 18/2005

Octocog alfa, Plasma/Albumin-Free Method

Acknowledgement

Tigecycline

Tigecycline

Ropivacaine

Gout in Solid Organ Transplantation